Comprehensive turnkey scientific research, chemical standard setting, and translational pharmacological research capabilities validated across global botanical medicine standards.
A technical treatise on resolving multi-target complexity, variable bio-availability, and stringent international standards via modernized botanical contract development.
Traditional herbal extraction has long struggled with batch variations, indeterminate mechanism profiles, and non-linear efficacy curves. Modern CRO pipelines implement chromatographic fingerprinting, targeted multi-omics, and molecular affinity screening to convert crude poly-herbal mixtures into tightly controlled, drug-grade APIs.
Unlike monolithic synthetic compounds, natural extracts require sophisticated matrix deconvolution. Our research methodology utilizes bioactivity-directed assays to separate inactive bulk cellulose and tannins from target alkaloids, saponins, and flavonoids, drastically accelerating lead optimization.
Global regulatory agencies require exhaustive toxicology before clinical initiation. Contract research establishes definitive safety through OECD-compliant genotoxicity (Ames test), cellular micro-cytotoxicity, acute oral LD50 determination, and long-term 90-day repeat-dose rodent toxicology profiles.
Projecting the scientific trajectories of natural medicine discovery through 2030: where artificial intelligence intersects with synthetic biology and chemical informatics.
Machine learning models predict protein-ligand binding kinetics of complex botanical phytomolecules, reducing initial target validation timelines from 14 months to 6 weeks.
High-resolution quadrupole time-of-flight mass spectrometry unlocks non-targeted metabolomics to trace chemical markers across environmental shifts, soil chemistry, and elevations.
Replacing traditional batch reflux vessels with counter-current automated micro-reactors guarantees reproducible thermodynamic yields and cuts thermal degradation of sensitive glycosides.
Overcoming botanical water-insolubility with self-emulsifying drug delivery systems (SEDDS) and lipid-nanoparticle formulation research to drive human bioavailability up by over 450%.
Combining agrarian provenance, high-throughput pilot-scale bioreactors, and fully digitized MES systems to assure flawless batch-to-batch repeatability and scalable unit economics.
Our raw material sourcing spans directly managed Chinese agro-stations adhering to Good Agricultural Practices (GAP). Complete barcoded traceability documents seed lineage, fertilizer logs, heavy metal soil baseline data, and exact harvest calendar timing.
Integrated research-to-plant infrastructure eliminates margin leakage common in multi-tier supply channels. Rapid pilot scale-up bridges the critical transition from 500-gram laboratory trial batches to multi-ton commercial OEM productions without re-validation lag.
Multi-stage resin separation, continuous vacuum low-temperature evaporation, and closed-loop spray drying towers are governed by SCADA control loops, mitigating human error and locking in consistent botanical API potency specs.
Engineered to mitigate risk for international procurement directors, VP of Formulations, and regulatory compliance heads across three core sectors.
Overcome FDA DSHEA and EFSA regulatory friction with pre-validated human clinical data, precise fingerprint assay standardization, guaranteed free from microbial contaminants, adulterants, synthetic spikes, or undeclared pharmaceutical enhancers.
Full support for Botanical Drug Development Guidance pathways (US FDA & NMPA). Rigorous documentation covering CMC stability, in vitro receptor binding assays, GLP animal models, and Phase 1-4 clinical cohort governance.
Accelerate claims substantiation for skin repair, anti-inflammatory, and tyrosinase inhibition pathways. Comprehensive safety dossiers including patch testing, human repeat insult patch tests (HRIPT), and transdermal penetration kinetics.
Safeguarding corporate IP assets and ensuring frictionless clearance through multi-jurisdictional audits, pharmacopeia standards, and custom regulatory dossiers.
Analytical method development adheres dynamically to current United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Chinese Pharmacopoeia (ChP) testing frameworks, ensuring straightforward regulatory filings.
We implement airtight legal firewalls under non-disclosure frameworks. Process engineering blueprints, unique molecular purification methods, and client formulation recipes are segregated across encrypted project environments.
Every commercial or pilot deliverable comes supported by comprehensive Certificate of Analysis (CoA), validated method SOPs, stability study reports (accelerated and long-term ICH conditions), and complete raw material provenance trails.
Seamlessly transitioning laboratory breakthroughs into scalable commercial executions across all compliant natural dosage forms and API morphologies.
In-depth responses clarifying analytical capabilities, transfer workflows, IP ownership, and clinical trial oversight.